

## This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Cancer</b>				
Cancer	V-set domain containing T cell activation inhibitor 1 (B7-H4; VTCN1)	<p>Studies in mice and patient samples suggest antibodies against B7-H4 could help treat cancer. In staining studies on patient tumor tissues, anti-B7-H4 mAbs bound to antigen in ten different cancer types. <i>In vitro</i>, an anti-B7-H4 mAb killed cancer cells via antibody-dependent cellular cytotoxicity and neutralized B7-H4-mediated immunosuppression. In a mouse model of B7-H4-expressing colon cancer, an anti-B7-H4 mAb increased survival compared with a control IgG. Next steps include exploring mechanisms of anti-B7-H4 immunotherapy in different cancer types and evaluating combination therapy strategies.</p> <p><b>SciBX 7(46); doi:10.1038/scibx.2014.1345</b>                      Published online Dec. 4, 2014</p>	Patent application filed; licensing status undisclosed	<p>Jeon, H. <i>et al. Cell Rep.</i>; published online Oct. 30, 2014;                      doi:10.1016/j.celrep.2014.09.053  <b>Contact:</b> Xingxing Zang, Albert Einstein College of Medicine of Yeshiva University, Bronx, N.Y.                      e-mail: <a href="mailto:xing-xing.zang@einstein.yu.edu">xing-xing.zang@einstein.yu.edu</a>  <b>Contact:</b> Steven C. Almo, same affiliation as above                      e-mail: <a href="mailto:steve.almo@einstein.yu.edu">steve.almo@einstein.yu.edu</a></p>